In a phase 1 trial involving 53 patients with relapsed B-cell acute lymphoblastic leukemia received CD19-specific CAR T cells, and 44 patients (83%) had a complete remission (43). This evidence concerns the gene CD19 and B-cell acute lymphoblastic leukemia.